standard chemotherapy + bevacizumab

Standard chemotherapy + bevacizumab refers to a combination treatment regimen used as a control arm in clinical trials for advanced colorectal cancer, specifically the QLMA-CRC-IIT-001 study (NCT06293014) sponsored by Henan Cancer Hospital. This regimen consists of bevacizumab, a humanized monoclonal antibody that inhibits vascular endothelial growth factor (VEGF) to prevent tumor angiogenesis, combined with an investigator-selected standard chemotherapy backbone such as FOLFOX (5-fluorouracil, leucovorin, and oxaliplatin), FOLFIRI (5-fluorouracil, leucovorin, and irinotecan), or CAPEOX (capecitabine and oxaliplatin). The chemotherapy components act as cytotoxic agents by inhibiting thymidylate synthase, alkylating DNA, or inhibiting topoisomerase I, thereby suppressing tumor cell proliferation. This combination is evaluated as a second-line continuous therapy for patients who have achieved disease control after induction therapy.

Brand names

Avastin

Other names

standard chemotherapy + bevacizumab-Henan Cancer Hospital-colorectal cancerFOLFOX + bevacizumabFOLFIRI + bevacizumabCAPEOX + bevacizumab